These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38260414)

  • 1. Genomic dissection and mutation-specific target discovery for breast cancer
    Miranda AX; Kemp J; Davidson B; Bellomo SE; Agan V; Manoni A; Marchiò C; Croessmann S; Park BH; Hodges E
    bioRxiv; 2024 Jan; ():. PubMed ID: 38260414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic dissection and mutation-specific target discovery for breast cancer PIK3CA hotspot mutations.
    Miranda AX; Kemp J; Davidson BA; Bellomo SE; Miranda VE; Manoni A; Marchiò C; Croessmann S; Park BH; Hodges E
    BMC Genomics; 2024 May; 25(1):519. PubMed ID: 38802751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
    Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE
    Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
    Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
    Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM
    JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations.
    Blair BG; Wu X; Zahari MS; Mohseni M; Cidado J; Wong HY; Beaver JA; Cochran RL; Zabransky DJ; Croessmann S; Chu D; Toro PV; Cravero K; Pandey A; Park BH
    Proteomics; 2015 Jan; 15(2-3):318-26. PubMed ID: 25367220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
    Zhou J; Imani S; Shasaltaneh MD; Liu S; Lu T; Fu J
    Mol Biol Rep; 2022 Mar; 49(3):1799-1816. PubMed ID: 34816327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
    Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H
    Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
    Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
    Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
    Kong D; Yamori T; Yamazaki K; Dan S
    Invest New Drugs; 2014 Dec; 32(6):1134-43. PubMed ID: 25152245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
    Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M; González-Farré B; Sanfeliu E; Schettini F; Conte B; Brasó-Maristany F; Rodríguez A; Martínez D; Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A
    Breast Cancer Res; 2020 May; 22(1):45. PubMed ID: 32404150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
    Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT
    Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivities and Dependencies of
    Voutsadakis IA
    Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295658
    [No Abstract]   [Full Text] [Related]  

  • 18. [Correlation between the incidence of PIK3CA mutations in breast cancer and histopathological characteristics of the tumor].
    Mendelová A; Jezková E; Zubor P; Holubeková V; Lasabová Z; Plank L; Danko J
    Ceska Gynekol; 2014 Aug; 79(4):283-8. PubMed ID: 25398149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
    Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M
    Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.